Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AstraZeneca Pharma shares rally 13%, hit 52-week high
AstraZeneca shares rally 13%, hit record high as firm gets nod for cancer drug
Astrazeneca Pharma India has received CDSO's (Central Drugs Standard Control Organisation) nod for the import of Durvalumab for its sale and distribution.
AstraZeneca Pharma shares rally 13%, hit 52-week high after receiving nod for cancer drug Durvalumab
The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages (SMAs).
AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12%
The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.
AstraZeneca Pharma gets nod to sell immunotherapy drug Durvalumab; stock surges
This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.
AstraZeneca Pharma Gets Approval To Import And Distribute Durvalumab For Cancer Treatment
This approval allows Durvalumab to be used together with chemotherapy before surgery, and then as a single treatment afterward.
AstraZeneca Pharma Surges on CDSO Approval for Durvalumab in India
AstraZeneca Pharma India has received approval from the CDSO for the import, sale, and distribution of Durvalumab.
Lung cancer drug: AstraZeneca India wins CDSCO nod for Durvalumab for specified additional indication
Bengaluru: AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion from the Central
AstraZeneca India gets CDSCO nod for its chemotherapy drug additional indications
According to GLOBOCAN 2022 data, lung cancer remains the fourth most common cause of cancer-related mortality in India.
AstraZeneca Pharma gets approval to launch cancer drug in India
This is to inform you that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India, to import and distribute Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi), according to a stock exchange filing.
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial
Key Takeaways A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial.The trial included over 700 patients with inoperable or metastatic breast cancer.
14h
AstraZeneca: Buy This Big Pharma Stock At A Discount Now
AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...
FiercePharma
11h
AstraZeneca shows ‘What Science Can Do’ for patients’ lives in new video series
The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...
1d
AstraZeneca Pharma shares jump 12% to 52-week high on CDSCO permission
The company has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Would-be assassin charged
Gets 2-yrs for role in fraud
Diagnosed with Parkinson's
Woman dies in 'suicide pod’
‘Trump Train’ jury verdict
Food packaging cancer risk
Haitian group files complaint
Outlaws guitarist dies
Contempt charge coming?
Won't call special session
Rioter mistakenly released
Phoenix breaks heat record
To shut down TikTok Music
Foreign incentives offer?
Helene forms in Caribbean
Dali owner, operator sued
1st NL East title since 2011
Partners with Google
Calls for US to lift sanctions
EEOC blocked on rules
PA county ballot ruling
ISR: Hezbollah leader killed
NC sending absentee ballots
X account hacked
Executed by lethal injection
Retiring after 14 seasons
Recalls 41K+ motorcycles
Study about oceans' acidity
Severe obesity on the rise
OR removes 1,200+ voters
Feedback